No Data
Nearshore Protein (688137.SH): has repurchased 0.4992% of the shares accumulated.
On November 4th, GeLongHui announced that as of October 31, 2024, the company has cumulatively repurchased 350,337 shares for employee stock ownership plans or stock-based incentives through centralized competitive trading on the Shanghai Stock Exchange, accounting for 0.4992% of the total share capital of 70,175,439 shares. The highest repurchase price was 33.00 yuan per share, and the lowest price was 28.75 yuan per share, with a total amount paid of RMB 10,346,681.909 (excluding stamp duty, trading commissions, and other transaction costs). For stability purposes.
Third Quarter Report 2024
Nearshore protein (688137.SH): a net loss of 18.2585 million yuan in the first three quarters.
Hua Rong Hui announced its third quarter report on October 29. The revenue for the first three quarters was 92.079 million yuan, a decrease of 16.83% year-on-year. The net loss was 18.2585 million yuan, and the non-net loss was 32.707 million yuan. The basic earnings per share was -0.2602 yuan.
Nearshore Protein (688137.SH): Shareholders such as Nanjing Jinli and Suzhou Jinling plan to reduce their holdings.
On October 18, Gelonghui announced that shareholders such as Nanjing Jinli, Suzhou Jinling, and others plan to reduce their holdings of the company's shares through centralized bidding, block trading, inquiry transfer, etc., due to their own operational development and capital needs. The reduction price of the shareholders is determined by the market price, and the reduction period is within three months after the disclosure date of this announcement for the next three trading days. Qiaobe from Heze will reduce by no more than 0.2832%; Nanjing Jinli will reduce by no more than 1.0189%; Suzhou Jinling will reduce by no more than 1.0189%; Hangzhou Changsui will reduce by no more than 0.3750%; Zibo Jingli
Nearshore Protein (688137.SH): Intends to temporarily idle the raised funds of not more than 1 billion yuan for cash management.
On October 16, Geelong announced that the company plans to use temporarily idle funds not exceeding RMB 1 billion (including the principal amount) for cash management. Within the aforementioned limit, the funds can be used flexibly, with a validity period of 12 months from the date of approval by the board of directors.
Novoprotein Scientific Inc.'s (SHSE:688137) Market Cap Surged CN¥449m Last Week, Private Companies Who Have a Lot Riding on the Company Were Rewarded
